Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8502974 | 0.83 | FABP7 (0.58) | FABP7FABP5ALDH1A1MMP9MMP1 | |
| SCHEMBL8191635 | 0.83 | FABP7 (0.58) | FABP7FABP5ALDH1A1MMP9MMP1 | |
| SCHEMBL2209386 | 0.82 | TDP1 (0.50) | FABP7FABP5ALDH1A1KMT2A | |
| SCHEMBL27793138 | 0.81 | ALDH1A1 (0.61) | FABP7FABP5ALDH1A1KMT2A | |
| SCHEMBL28813611 | 0.81 | ALDH1A1 (0.57) | FABP7FABP5ALDH1A1KMT2A | |
| SCHEMBL14722678 | 0.79 | FABP7 (0.51) | FABP7FABP5ALDH1A1MMP9MMP1 | |
| SCHEMBL8587581 | 0.79 | ALDH1A1 (0.63) | FABP7FABP5ALDH1A1KMT2A | |
| SCHEMBL8477590 | 0.78 | FABP7 (0.60) | FABP7FABP5ALDH1A1 | |
| SCHEMBL3736983 | 0.78 | FABP7 (0.53) | FABP7FABP5ALDH1A1MMP9MMP1 | |
| SCHEMBL10639541 | 0.78 | FABP7 (0.60) | FABP7FABP5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794605-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| CN-104024248-A | SERINE/THREONINE PAK1 INHIBITORS | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| CN-104011050-A | 2, 4-diamino-pyrimidine derivatives as serine/threonine kinase inhibitors | HOFFMANN LA ROCHE | 2014-08-27 | — | — | CN | disclosed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | FABP7 4849/4885FABP5 4863/4885RXFP1 1047/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | FABP7 4626/4885FABP5 4572/4885RXFP1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.